hydromorphone hydrochloride

FDA Drug Profile — hydromorphone hydrochloride, Hydromorphone Hydrochloride, HYDROMORPHONE HYDROCHLORIDE, Dilaudid

hydromorphone hydrochloride is listed in the FDA National Drug Code directory with 28 NDC codes, marketed under brand names including hydromorphone hydrochloride, Hydromorphone Hydrochloride, HYDROMORPHONE HYDROCHLORIDE. Available dosage forms: tablet, extended release, tablet, solution.

Drug details

Generic Name
hydromorphone hydrochloride
Brand Names
hydromorphone hydrochloride, Hydromorphone Hydrochloride, HYDROMORPHONE HYDROCHLORIDE, Dilaudid
Application Number
ANDA212133
Sponsor
XLCare Pharmaceuticals, Inc.
NDC Codes
28
Dosage Forms
TABLET, EXTENDED RELEASE, TABLET, SOLUTION
Routes
ORAL
Active Ingredients
HYDROMORPHONE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions ( 5.2 )] , reserve opioid analgesics, including hydromorphone hydrochloride tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Hydromorphone hydrochloride tablets contain hydromorphone, an opioid agonist, and are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including hydromorphone hydrochloride tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.2 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.